- Home
- BCAB vs ONCY Comparison
BCAB vs ONCY Comparison
Compare BCAB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ONCY
- Stock Information
- Founded
- BCAB 2007
- ONCY 1998
- Country
- BCAB United States
- ONCY Canada
- Employees
- BCAB N/A
- ONCY N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ONCY Pharmaceuticals and Biotechnology
- Sector
- BCAB Health Care
- ONCY Health Care
- Exchange
- BCAB Nasdaq
- ONCY Nasdaq
- Market Cap
- BCAB 96.2M
- ONCY 103.8M
- IPO Year
- BCAB 2020
- ONCY 1999
- Fundamental
- Price
- BCAB $2.08
- ONCY $1.19
- Analyst Decision
- BCAB Strong Buy
- ONCY Strong Buy
- Analyst Count
- BCAB 2
- ONCY 2
- Target Price
- BCAB $6.00
- ONCY $4.00
- AVG Volume (30 Days)
- BCAB 1.6M
- ONCY 903.7K
- Earning Date
- BCAB 11-08-2024
- ONCY 11-05-2024
- Dividend Yield
- BCAB N/A
- ONCY N/A
- EPS Growth
- BCAB N/A
- ONCY N/A
- EPS
- BCAB N/A
- ONCY N/A
- Revenue
- BCAB N/A
- ONCY N/A
- Revenue This Year
- BCAB N/A
- ONCY N/A
- Revenue Next Year
- BCAB N/A
- ONCY N/A
- P/E Ratio
- BCAB N/A
- ONCY N/A
- Revenue Growth
- BCAB N/A
- ONCY N/A
- 52 Week Low
- BCAB $1.14
- ONCY $0.84
- 52 Week High
- BCAB $4.02
- ONCY $1.80
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- ONCY 52.51
- Support Level
- BCAB $1.87
- ONCY $1.17
- Resistance Level
- BCAB $2.13
- ONCY $1.28
- Average True Range (ATR)
- BCAB 0.12
- ONCY 0.09
- MACD
- BCAB 0.00
- ONCY -0.01
- Stochastic Oscillator
- BCAB 68.90
- ONCY 28.00
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.